Highlights

  • Biome Australia (ASX:BIO) shares closed at A$0.36, up 4.35% on 9 September 2026.
  • FY26 sales Revenue reached A$23.88 million, representing growth of almost 30% from A$18.42 million in FY25.
  • Net profit increased to A$3.61 million, compared with A$0.21 million in the previous financial year.
  • Investors are likely to monitor domestic pharmacy growth, international expansion, product launches, cash generation and execution against the company’s longer-term growth strategy.

Biome Australia Limited (ASX:BIO) shares finished Wednesday higher, closing at A$0.36, up 4.35% on 9 September 2026.

The broader Australian market moved modestly lower. The S&P/ASX 200 (ASX:XJO) closed at 8,911.40 points, down 0.11% on 9 September 2026, while the S&P/ASX 300 (ASX:XKO) finished at 8,842.30 points, down 0.12%.

Consumer Staples also ended in positive territory, with the S&P/ASX 200 Consumer Staples (ASX:XSJ) closing at 13,170.4 points, up 0.25% on 9 September 2026.

BIO therefore outperformed both the broader Australian market and the Consumer Staples benchmark during the session. However, the 4.35% share-price gain should not automatically be attributed to any specific announcement. Short-term price movements can reflect investor positioning, Liquidity and changing market expectations, while the company’s longer-term performance will depend on sales growth, margins, product adoption and cash generation.

Microbiome Platform

Biome Australia develops, commercialises and markets evidence-based microbiome health products, including live biotherapeutics and complementary medicines.

Its principal consumer Brand is Activated Probiotics, a practitioner-focused range designed around targeted applications such as digestive health, immune health, mood, sleep, skin health and other areas. The products are distributed primarily through pharmacies, nutrition professionals and other practitioner channels.

BIO’s Business model is built around developing clinically supported formulations and then scaling them through professional recommendation and retail distribution.

This positioning differentiates the company from mass-market supplement businesses that compete primarily on branding or price. For investors, the important commercial questions are whether clinical differentiation can support repeat demand, whether distribution can continue expanding and whether international markets can develop into meaningful Earnings contributors.

FY26 Results

BIO reported FY26 earnings in late August 2026, providing the most relevant recent financial update for investors.

Sales revenue increased to A$23.88 million for the year ended 30 June 2026, compared with A$18.42 million in FY25, representing growth of approximately 29.7%. Net profit increased to A$3.61 million from A$0.21 million a year earlier.

The increase represented a significant step up in profitability following the company’s first full-year profit in FY25.

BIO had already shown progress during the first half. H1 FY26 sales revenue reached A$12.40 million, up 40% on the previous corresponding period, while net profit after tax was A$1.18 million. Underlying EBITDA was A$0.81 million, and cash generated from operations reached A$2.09 million.

The stronger full-year result suggests growth remained meaningful through the second half, although investors are likely to focus increasingly on the sustainability of margins and cash conversion as the revenue base becomes larger.

Domestic Momentum

Australia remains the foundation of BIO’s commercial model.

The company said FY26 annual sales reached approximately A$23.9 million, while June marked the first month in which consumer sell-through of Activated Probiotics exceeded 100,000 units. Management also said Biome Daily had become the leading probiotic product in Australian pharmacy by units and dollar value based on the market data cited by the company.

For investors, this is relevant because consumer sell-through measures actual movement of product from retail shelves rather than simply shipments into the distribution channel.

Sustained sell-through can help indicate whether distribution growth is being supported by genuine end-customer demand.

However, the next stage is likely to require growth across a broader product portfolio rather than dependence on one flagship product. BIO has been expanding its Activated Probiotics and Activated Therapeutics ranges and has indicated further product launches are planned as it progresses through FY27.

International Expansion

International markets remain another important growth avenue.

BIO has established distribution arrangements across countries including New Zealand, Canada and Ireland, while international expansion remains central to its strategic growth framework.

The company has spent recent periods building pharmacy and practitioner distribution networks outside Australia. These markets provide additional revenue potential, but international expansion can also create higher marketing, regulatory and logistics costs before meaningful scale is reached.

In June 2026, BIO also announced an Australian Manufacturing agreement, adding another element to its supply-chain strategy as the company seeks to support future product growth.

Investors may therefore assess not simply the number of international markets entered, but whether those markets generate improving sales productivity and margins over time.

What Investors May Watch

BIO’s 4.35% increase on 9 September 2026 represents a comparatively strong daily move, but one session alone does not determine the longer-term Investment case.

Revenue growth remains one of the clearest metrics to watch. FY26 sales of A$23.88 million represented another step up from FY25, but sustaining similar growth rates becomes progressively more demanding as the base expands.

Profitability and cash generation will also be important. BIO has moved from losses to positive earnings and reported meaningful operating cash generation during H1 FY26. Maintaining that progress while continuing to fund product development and international expansion will be a key measure of execution.

Investors may also monitor pharmacy distribution, practitioner engagement, new product launches and the performance of markets outside Australia.

Valuation considerations could become increasingly tied to whether BIO develops into a sustainably profitable health-products platform rather than simply a fast-growing small-cap company.

Final Takeaway

Biome Australia (ASX:BIO) shares closed at A$0.36, up 4.35% on 9 September 2026, outperforming both the broader Australian market and the S&P/ASX 200 Consumer Staples Index.

The more meaningful fundamental development is the company’s FY26 performance. Sales increased to A$23.88 million from A$18.42 million, while net profit rose to A$3.61 million from A$0.21 million.

For investors, the next phase is likely to be defined by domestic pharmacy growth, international expansion, product launches, operating margins and cash generation. If BIO can sustain revenue growth while maintaining profitability, the business may continue to build greater scale across the microbiome health market. Those measures are likely to matter more to the longer-term outlook than a single day’s share-price gain.